Breaking
Vast Magma System Found Beneath Mars UN Warns ‘Supersized’ El Niño Could Be Strongest in Decades Commercial Property Engulfed in Hatigaon Morning Fire 2,000 Students Fall Sick After School Meals in Indonesia; Rights Body Seeks Probe Guests Leave 3 Women Unconscious, Steal Valuables Vast Magma System Found Beneath Mars UN Warns ‘Supersized’ El Niño Could Be Strongest in Decades Commercial Property Engulfed in Hatigaon Morning Fire 2,000 Students Fall Sick After School Meals in Indonesia; Rights Body Seeks Probe Guests Leave 3 Women Unconscious, Steal Valuables
MinuteBrief logo
Business

Natco Pharma Raises Total Funding to $22 Million for eGenesis Initiatives

Natco Pharma has invested $14 million in eGenesis, bringing its total investment to $22 million to fund genome-engineered organs development.

Methly Agarwal | | 1 min read

Natco Pharma Raises Total Funding to $22 Million for eGenesis Initiatives
AI generated image | Minutebrief Team

In Brief

  1. Natco Pharma infused an additional $14M into U.S. biotech company eGenesis, raising total funding to $22M.
  2. Delivered via convertible promissory notes through Canadian ($9.5M) and South African ($4.5M) subsidiaries.
  3. Deepens Natco's exposure to eGenesis' work in developing genome-engineered, human-compatible organs to solve global transplant shortages.

Natco Pharma has increased its financial commitment to U.S.-based biotechnology company eGenesis with an additional $14 million investment, bringing its total investment to $22 million. The funding is structured through convertible promissory notes issued by eGenesis to Natco Pharma's subsidiaries, with Natco Pharma (Canada) Inc. contributing $9.5 million and Natco Pharma South Africa Proprietary Ltd investing $4.5 million.

This move deepens Natco Pharma's strategic involvement and financial exposure to eGenesis, supporting its work in genetic engineering to develop human-compatible organs for transplantation and address the critical global shortage of donor organs.

More from Business